Biomarkers for immune checkpoint inhibitors - Authors' reply

The Lancet Oncology

Volumn 15, Issue 1, 2014, Pages

  Calabrò, Luana ^a   Maio, Michele ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; TICILIMUMAB; ANTINEOPLASTIC AGENT;

BLOCKING FACTOR; CANCER CELL; CANCER CELL CULTURE; CELL SURFACE; CUTANEOUS MELANOMA; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; IMMUNE CHECKPOINT BLOCKING; IMMUNE RESPONSE; LETTER; MESOTHELIOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; DRUG EFFECT; DRUG RESISTANCE; FEMALE; MALE; NOTE; PLEURA TUMOR; SALVAGE THERAPY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MESOTHELIOMA; PLEURAL NEOPLASMS; SALVAGE THERAPY;

EID: 84891359527     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70573-4     Document Type: Letter

References (4)

1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
2. Callahan M, Horak CE, Curran MA, et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. Proc Am Soc Clin Oncol 2013, 31(suppl). abstr 3003.
3. Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013, 14:1104-1111.
4. Di Giacomo AM, Calabrò L, Danielli R, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013, 62:1021-1028.